Johnson & Johnson Gmbh

Ortho Pharmaceutical Corporation

Johnson & Johnson Consumer Companies, Inc.

James A Mezick

John R Marvel

David T Rovee

Albert M Kligman

Robert J Capetola

Gerard J Gendimenico

Richard K Farng

Shirley M Ng

Stanley B Wrobel, Jr

D Thomas Rovee

The present invention relates to a method for treatment of mammalian skin conditions where stimulated connective tissue synthesis is beneficial, comprising treating skin in need of such treatment with a safe and effective amount of 17-&agr;-estradiol.

Use of 17-&agr;-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy

This invention relates to aqueous gel retinoid compositions and their methods of use. More specifically, the aqueous gel retinoid compositions of the invention utilize micronized particles of retinoids, particularly tretinoin, to provide an aqueous gel for topical application of such retinoids to the skin which minimizes skin irritation while retaining drug efficacy.

Aqueous gel retinoid dosage form

The present invention is directed to the topical administration of a retinoid-containing pharmaceutical composition for reversing the effects of glucocorticoid-induced skin atrophy.

Reversal of glucocorticoid-induced skin atrophy

The present invention is directed to the topical administration of a retinoid-containing pharmaceutical composition for the prevention of glucocorticoid-induced skin atrophy.

Prevention of glucocorticoid-induced skin atrophy

A pharmaceutical composition for topical treatment of cutaneous disorders or disruptions characterized by skin inflammation or hyperproliferative epidermal activity comprises the combination of a topically active anti-inflammatory corticosteroid and a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolon derivatives; the fenamic acid derivatives; the aroyl-substituted pyrroles and the substituted arylacetohydroxamic acids in a pharmaceutically acceptable topical vehicle. Treatment of above cutaneous disorders may also be effected by concurrent therapy using separate applications of corticosteroid and non-steroid.

Topical anti-inflammatory drug therapy

Topical treatment of non-inflammatory acne by the administration of 13-cis-retinoic acid is disclosed.

Topical treatment of non-inflammatory acne

A pharmaceutical composition for topical treatment of cutaneous disorders or disruptions characterized by skin inflammation or hyperproliferative epidermal activity comprises the combination of a topically active anti-inflammatory corticosteroid and a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolone derivatives; the fenamic acid derivatives; the aroyl-substituted pyrroles and the substituted arylacetohydroxamic acids in a pharmaceutically acceptable topical vehicle. Treatment of above cutaneous disorders may also be effected by concurrent therapy using separate applications of corticosteroid and non-steroid.

Tretinoin is incorporated in the adhesive mass of a dermatologically acceptable pressure-sensitive adhesive tape for the localized topical treatment of such skin conditions as acne and warts.

Growing community of inventors

East Brunswick, NJ, United States of America

James A Mezick